title: [Oscillation between BK virus nephropathy and rejection--the frustrating course of a living donor transplantation].
abstract: METHODS
  A 56-year-old male patient with terminal renal insufficiency received a living donor kidney transplant from his wife in June 2007. Initial immunosuppression consisted of prednisolone, tacrolimus, and mycophenolate mofetil (MMF). 4 months after transplantation, the serum creatinine increased to 192 micromol/l and urinary analysis revealed the presence of decoy cells. A biopsy showed a focal interstitial nephritis and SV40 antigen was detected in tubular nuclei. Polymerase chain reaction (PCR) in serum and urine showed high titers of BK virus. Tacrolimus was stopped, MMF was reduced, and leflunomide (20 mg/day) was started. The patient was readmitted because the serum creatinine further increased to 262 micromol/l. Leflunomide concentrations were in the target range, but renal biopsy still revealed the presence of BK virus nephropathy. MMF was stopped. Serum creatinine stabilized at 233 micromol/l and PCR for BK virus in serum was negative. In April 2008, a deterioration of renal function occurred (serum creatinine 308 micromol/l) and renal biopsy revealed signs of acute interstitial rejection without the presence of SV40 antigen. A methylprednisolone pulse therapy for 5 days was performed and cyclosporine was added. After a few weeks serum creatinine increased to 444 micromol/l and a new biopsy revealed the reoccurrence of BK virus nephropathy. Since the tubulointerstitial injury was > 80%, no further therapy was performed and soon after dialysis therapy was initiated.
  
  
  CONCLUSIONS
  BK virus nephropathy is a still rare, but increasing complication of renal transplantation, presumably mediated by intensive immunosuppression. The disease can induce graft dysfunction and may ultimately lead to graft failure. BK virus nephropathy can trigger acute rejection. Unfortunately, therapy of BK virus nephropathy and acute rejection is just the opposite: BK virus nephropathy requires a reduction of immunosuppression whereas acute rejection calls for intensification. A potential therapeutic approach may be leflunomide, an immunosuppressive substance with antiviral properties, but potential severe side effects. The described case demonstrates the frustrating course of a graft from a living donor despite initial successful therapy with leflunomide and illustrates the problems choosing between intensive and moderate immunosuppression.
authors.affiliation: Klinik für Innere Medizin III, Friedrich-Schiller-Universität Jena, Jena, Germany.
authors.forename: Christine
authors.initials: C
authors.lastname: Materne
authors.forename: Jens
authors.initials: J
authors.lastname: Gerth
authors.forename: Undine
authors.initials: U
authors.lastname: Ott
authors.forename: Hermann-Josef
authors.initials: HJ
authors.lastname: Gröne
authors.forename: Gunter
authors.initials: G
authors.lastname: Wolf
mesh_terms: D001739:BK Virus; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000473:pathology / Q000601:surgery*; D016030:Kidney Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009395:Nephritis, Interstitial / Q000175:diagnosis* / Q000473:pathology; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000473:pathology; D027601:Polyomavirus Infections / Q000175:diagnosis* / Q000473:pathology; D011183:Postoperative Complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D014412:Tumor Virus Infections / Q000175:diagnosis* / Q000473:pathology
chemical_list: D007166:Immunosuppressive Agents; D003404:Creatinine
references.citation: Clin J Am Soc Nephrol. 2007 Jul;2 Suppl 1:S36-46
references.pmid: 17699509
references.citation: Transplantation. 2009 Mar 15;87(5):621-30
references.pmid: 19295303
references.citation: N Engl J Med. 2002 Aug 15;347(7):488-96
references.pmid: 12181403
references.citation: Nephrol Dial Transplant. 2003 Jun;18(6):1190-6
references.pmid: 12748354
references.citation: Antivir Ther. 2008;13(8):1001-9
references.pmid: 19195325
references.citation: Nephrol Dial Transplant. 2006 Jul;21(7):2039-40
references.pmid: 16644781
references.citation: Clin J Am Soc Nephrol. 2008 May;3(3):829-35
references.pmid: 18372319
references.citation: Am J Kidney Dis. 2009 Jul;54(1):131-42
references.pmid: 19394729
references.citation: N Engl J Med. 2002 Aug 15;347(7):527-30
references.pmid: 12181409
references.citation: Clin Infect Dis. 2005 Feb 15;40(4):528-37
references.pmid: 15712075
references.citation: Am J Transplant. 2006 May;6(5 Pt 1):1025-32
references.pmid: 16611340
references.citation: Ann Pharmacother. 2008 Nov;42(11):1679-85
references.pmid: 18957628
references.citation: N Engl J Med. 2005 Mar 17;352(11):1157-8
references.pmid: 15784677
references.citation: Transplantation. 2007 Aug 15;84(3):340-5
references.pmid: 17700158
references.citation: Transplantation. 2005 May 27;79(10):1277-86
references.pmid: 15912088
references.citation: Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii66-viii71
references.pmid: 17890267
references.citation: Clin J Am Soc Nephrol. 2008 May;3(3):652-3
references.pmid: 18385395
references.citation: Am J Transplant. 2006 Sep;6(9):2000-5
references.pmid: 16771813
references.citation: Clin Nephrol. 2008 Apr;69(4):244-50
references.pmid: 18397698
references.citation: J Antimicrob Chemother. 2008 Nov;62(5):855-9
references.pmid: 18658193
references.citation: Am J Transplant. 2005 Mar;5(3):582-94
references.pmid: 15707414
references.citation: Am J Transplant. 2005 Dec;5(12):2883-93
references.pmid: 16303001